Consumer Alert: Antidepressants During Pregnancy Could Harm Your Baby

New research finds SSRIs cross the placenta, exposing fetuses to risky chemicals without mothers' informed consent. Alternatives exist with no evidence of harm

A recent pilot study published in The International Journal of Neuropsychopharmacology indicates that common antidepressant drugs known as SSRIs (selective serotonin reuptake inhibitors) have the ability to cross the placental barrier, entering the fetal bloodstream.¹ Previous research also suggests these compounds cross the blood-brain barrier and bioaccumulate in fetal tissue.^2,3

The study tested SSRI concentrations in cord blood samples from 15 neonates born to medicated mothers. Measurable levels of paroxetine, sertraline, and venlafaxine were found in 13 infants' samples.¹ Maternal and fetal drug concentrations were similar in most cases.

These findings raise significant concerns about understudied toxicity risks of prenatal SSRI exposure during complex developmental processes. Though SSRIs aim to increase serotonin availability in the brain, research remains inconclusive on whether chemical imbalances of neurotransmitters definitively cause depression or explain the mechanism of these drugs.^4,5 This is sometimes called the "serotonin-" or "monoamine hypothesis" and has been heavily criticized by alternative psychiatrists in the past. Meanwhile, it the medical community is beginning to recognize that artificially altering fetal serotonin levels with novel, synthetic chemical compounds could adversely impact cell proliferation, differentiation, synaptogenesis, and myelination.⁶

Studies have already associated prenatal SSRI exposure with increased risks of major malformations,⁷ persistent pulmonary hypertension,⁸ autism spectrum disorders,⁹ and long-term neurobehavioral disturbances.¹⁰ However, due to limitations around proving toxicity in human subjects and the resistance that conventional medical journals have to publishing information that is contrary to promoting pharmaceutical drugs, authors posit that "conclusions remain speculative."¹¹ Still, concerning evidence like the kind featured in this latest study reveals the growing need for caution in prescribing these aggressively marketed medications.

Adding to the problem, pregnant women prescribed antidepressants rarely receive full information enabling informed consent about drug exposure risks for the fetus.¹² Respecting patient autonomy requires thorough disclosure about what is known and still unknown to allow informed decisions about prenatal treatments. 

Evidence-Based Alternatives to Antidepressants

Rather than expose fetuses to understudied SSRIs, research shows many non-pharmacological therapies effectively treat depression with little to no side effects. These include nutrition plans high in omega-3s, B vitamins, selenium; exercise regimens; mind-body practices like yoga, mindfulness, meditation; natural supplements; and light therapy, to name a few.¹³ For example, a meta-analysis of over 1500 human trials found saffron as effective as fluoxetine without adverse reactions.¹⁴

To learn more on natural antidepressive approaches, visit the extensive Greenmedinfo.com database on the subject covering 1500 studies and 300 natural substances here.